OverT Bio

Executive Summary

OverT Bio is a next-generation cell therapy company developing off-the-shelf, allogeneic treatments for solid tumors. The company integrates a genome-scale AI discovery platform with gamma delta T cell biology to identify novel genetic programs that enhance T cell function and overcome the immunosuppressive tumor microenvironment. This approach aims to deliver scalable, accessible, and potentially curative therapies for a broad patient population. Founded in 2021 and headquartered in San Diego, OverT Bio operates at the intersection of synthetic biology and artificial intelligence, positioning itself to address key limitations of current cell therapies, such as T cell exhaustion and manufacturing complexity. The company's platform has the potential to generate a pipeline of universal, ‘off-the-shelf’ cell products that can be administered without the need for patient-specific customization, thereby reducing cost and treatment delay. While OverT Bio is still in preclinical stages and has not disclosed specific lead candidates or funding details, its innovative strategy and focus on solid tumors—a significant unmet need—make it a compelling player in the cell therapy landscape.

Upcoming Catalysts (preview)

• H2 2026Discovery platform validation data at a major oncology conference70% success
• 2027Lead candidate nomination and IND-enabling studies initiation50% success
• 2026Series A funding round to support pipeline development60% success